PubMed

Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Havel LS, Li S, Li XJ.

Mol Brain. 2009 Jul 3;2(1):21.PMID: 19575804 [PubMed - in process]Related articlesFree article

Multiple pathways contribute to the pathogenesis of Huntington disease.

Li S, Li XJ.

Mol Neurodegener. 2006 Dec 16;1:19.PMID: 17173700 [PubMed]Related articlesFree article

Polyglutamine expansion diseases: failing to deliver.

Morfini G, Pigino G, Brady ST.

Trends Mol Med. 2005 Feb;11(2):64-70. Review.PMID: 15694868 [PubMed - indexed for MEDLINE]Related articles

Polyglutamine and neurodegeneration: structural aspects.

Masino L.

Protein Pept Lett. 2004 Jun;11(3):239-48. Review.PMID: 15182225 [PubMed - indexed for MEDLINE]Related articles

Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.

Nagai Y, Popiel HA.

Curr Pharm Des. 2008;14(30):3267-79. Review.PMID: 19075705 [PubMed - indexed for MEDLINE]Related articles

Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation.

Krol HA, Krawczyk PM, Bosch KS, Aten JA, Hol EM, Reits EA.

PLoS One. 2008 Jan 30;3(1):e1503.PMID: 18231590 [PubMed - indexed for MEDLINE]Related articlesFree article

Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.

Sugaya K, Matsubara S, Kagamihara Y, Kawata A, Hayashi H.

PLoS One. 2007 Jul 25;2(7):e635.PMID: 17653262 [PubMed]Related articlesFree article

The structural impact of a polyglutamine tract is location-dependent.

Robertson AL, Horne J, Ellisdon AM, Thomas B, Scanlon MJ, Bottomley SP.

Biophys J. 2008 Dec 15;95(12):5922-30. Epub 2008 Oct 10.PMID: 18849414 [PubMed - indexed for MEDLINE]Related articlesFree article

Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.

Saunders HM, Bottomley SP.

Protein Eng Des Sel. 2009 Aug;22(8):447-51. Epub 2009 Jul 9. Review.PMID: 19589877 [PubMed - indexed for MEDLINE]Related articles

Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases.

Li X, Li H, Li XJ.

Brain Res Rev. 2008 Nov;59(1):245-52. Epub 2008 Aug 23. Review.PMID: 18773920 [PubMed - indexed for MEDLINE]Related articlesFree article

Neuronal toxicity of expanded polyglutamine depends on intracellular distribution in addition to the expression level.

Satoh M, Shimada A, Kawamura N, Chiba Y, Yoshikawa K, Ishii S, Furukawa A, Kumagai N, Hosokawa M.

Neuropathology. 2008 Oct;28(5):485-96. Epub 2008 Mar 31.PMID: 18384512 [PubMed - indexed for MEDLINE]Related articles

N-terminal polyglutamine-containing fragments inhibit androgen receptor transactivation function.

Schiffer NW, Céraline J, Hartl FU, Broadley SA.

Biol Chem. 2008 Dec;389(12):1455-66.PMID: 18844449 [PubMed - indexed for MEDLINE]Related articles

Molecular origin of polyglutamine aggregation in neurodegenerative diseases.

Khare SD, Ding F, Gwanmesia KN, Dokholyan NV.

PLoS Comput Biol. 2005 Aug;1(3):230-5. Epub 2005 Aug 26.PMID: 16158094 [PubMed]Related articlesFree article

Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis.

Ocampo A, Zambrano A, Barrientos A.

FASEB J. . [Epub ahead of print]PMID: 20008543 [PubMed - as supplied by publisher]Related articles

Polyglutamine homopolymers having 8-45 residues form slablike beta-crystallite assemblies.

Sharma D, Shinchuk LM, Inouye H, Wetzel R, Kirschner DA.

Proteins. 2005 Nov 1;61(2):398-411.PMID: 16114051 [PubMed - indexed for MEDLINE]Related articles

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.

Herbst M, Wanker EE.

Curr Pharm Des. 2006;12(20):2543-55. Review.PMID: 16842177 [PubMed - indexed for MEDLINE]Related articles

Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases.

Sugaya K, Matsubara S.

Mol Neurodegener. 2009 Jul 15;4:29.PMID: 19602294 [PubMed - in process]Related articlesFree article

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.

Bauer PO, Nukina N.

J Neurochem. 2009 Sep;110(6):1737-65. Epub 2009 Jul 23. Review.PMID: 19650870 [PubMed - indexed for MEDLINE]Related articles

[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases]

Nagai Y.

Rinsho Shinkeigaku. 2009 Nov;49(11):913-6. Japanese. PMID: 20030247 [PubMed - in process]Related articles

Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity.

Suzuki E, Zhao Y, Ito S, Sawatsubashi S, Murata T, Furutani T, Shirode Y, Yamagata K, Tanabe M, Kimura S, Ueda T, Fujiyama S, Lim J, Matsukawa H, Kouzmenko AP, Aigaki T, Tabata T, Takeyama K, Kato S.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3818-22. Epub 2009 Feb 23.PMID: 19237573 [PubMed - indexed for MEDLINE]Related articlesFree article